NASDAQ:NVCR - NovoCure Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$29.70 +0.15 (+0.51 %)
(As of 05/23/2018 03:09 AM ET)
Previous Close$29.55
Today's Range$29.47 - $29.95
52-Week Range$11.50 - $30.25
Volume365,400 shs
Average Volume931,033 shs
Market Capitalization$2.66 billion
P/E Ratio-42.43
Dividend YieldN/A
Beta3.07

About NovoCure (NASDAQ:NVCR)

NovoCure logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Debt-to-Equity Ratio1.41
Current Ratio6.32
Quick Ratio5.87

Price-To-Earnings

Trailing P/E Ratio-42.43
Forward P/E Ratio-49.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.03 million
Price / Sales15.22
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book23.39

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-33.12%
Return on Equity-56.70%
Return on Assets-23.65%

Miscellaneous

Employees495
Outstanding Shares90,700,000

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

How were NovoCure's earnings last quarter?

NovoCure (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, April, 26th. The medical equipment provider reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.10. The medical equipment provider earned $52.13 million during the quarter, compared to analysts' expectations of $57.13 million. NovoCure had a negative net margin of 33.12% and a negative return on equity of 56.70%. View NovoCure's Earnings History.

When is NovoCure's next earnings date?

NovoCure is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for NovoCure.

What price target have analysts set for NVCR?

5 analysts have issued 12-month target prices for NovoCure's shares. Their forecasts range from $15.00 to $33.00. On average, they anticipate NovoCure's share price to reach $24.75 in the next year. View Analyst Ratings for NovoCure.

What are Wall Street analysts saying about NovoCure stock?

Here are some recent quotes from research analysts about NovoCure stock:
  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (5/1/2018)
  • 2. Mizuho analysts commented, "We now anticipate a potential FDA approval for the mesothelioma indication before year-end 2018 given the company’s filing under Humanitarian Device Exemption. We updated our model to reflect revenues from mesothelioma in the coming years and raise our PT to $32." (4/18/2018)

Who are some of NovoCure's key competitors?

Who are NovoCure's key executives?

NovoCure's management team includes the folowing people:
  • Mr. William F. Doyle, Exec. Chairman (Age 56)
  • Mr. Asaf Danziger, CEO & Director (Age 52)
  • Mr. Kinyip Gabriel Leung, Vice Chairman & Chairman of the Global Commercialization Team (Age 56)
  • Prof. Yoram Palti, Founder, CTO & Director (Age 80)
  • Mr. Wilhelmus C. M. Groenhuysen, CFO & Principal Accounting Officer (Age 60)

Has NovoCure been receiving favorable news coverage?

News articles about NVCR stock have been trending somewhat positive on Wednesday, Accern reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NovoCure earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 45.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.16%), Baillie Gifford & Co. (3.03%), Farallon Capital Management LLC (2.04%), StepStone Group LP (1.51%), Tamarack Advisers LP (1.23%) and Frontier Capital Management Co. LLC (1.22%). Company insiders that own NovoCure stock include Asaf Danziger, Eilon D Kirson, Gabriel Leung, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for NovoCure.

Which institutional investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including StepStone Group LP, Millennium Management LLC, Cortina Asset Management LLC, Westfield Capital Management Co. LP, JPMorgan Chase & Co., A.R.T. Advisors LLC, Pier Capital LLC and BlackRock Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for NovoCure.

Which institutional investors are buying NovoCure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., PointState Capital LP, Loomis Sayles & Co. L P, Farallon Capital Management LLC, Allianz Asset Management GmbH, Nuveen Asset Management LLC, California Public Employees Retirement System and Tamarack Advisers LP. View Insider Buying and Selling for NovoCure.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $29.70.

How big of a company is NovoCure?

NovoCure has a market capitalization of $2.66 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. NovoCure employs 495 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for NovoCure (NVCR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NovoCure (NASDAQ:NVCR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for NovoCure in the last 12 months. Their average twelve-month price target is $24.75, suggesting that the stock has a possible downside of 16.67%. The high price target for NVCR is $33.00 and the low price target for NVCR is $15.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.862.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.75$21.00$20.8571$20.8571
Price Target Upside: 16.67% downside11.76% downside6.41% upside10.36% upside

NovoCure (NASDAQ:NVCR) Consensus Price Target History

Price Target History for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ:NVCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2018WedbushBoost Price TargetOutperform ➝ Outperform$29.00 ➝ $33.00LowView Rating Details
4/19/2018Deutsche BankUpgradeHold ➝ Buy$23.80 ➝ $19.00LowView Rating Details
4/18/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $32.00HighView Rating Details
11/20/2017JPMorgan ChaseReiterated RatingBuyN/AView Rating Details
5/24/2017Wells FargoUpgradeMarket Perform ➝ Outperform$15.00HighView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
7/29/2016BarclaysLower Price TargetUnderweight$12.00 ➝ $9.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

NovoCure (NASDAQ:NVCR) Earnings History and Estimates Chart

Earnings by Quarter for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ:NVCR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.22)($0.22)($0.22)

NovoCure (NASDAQ NVCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018($0.16)N/AView Earnings Details
4/26/20183/31/2018($0.13)($0.23)$57.13 million$52.13 millionViewN/AView Earnings Details
2/22/2018Before Market($0.14)($0.12)$53.17 million$53.66 millionViewListenView Earnings Details
10/26/20179/30/2017($0.20)($0.13)$43.45 million$50.10 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.23)($0.24)$42.20 million$38.38 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.32)$2.54$17.85 million$12.38 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NovoCure (NASDAQ:NVCR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NovoCure (NASDAQ NVCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 48.14%
Insider Trading History for NovoCure (NASDAQ:NVCR)
Institutional Ownership by Quarter for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ NVCR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Gabriel LeungDirectorSell80,000$28.83$2,306,400.00View SEC Filing  
5/14/2018Wilhelmus Cm GroenhuysenCFOSell30,470$30.04$915,318.80201,898View SEC Filing  
5/11/2018Wilhelmus Cm GroenhuysenCFOSell9,393$30.01$281,883.93201,898View SEC Filing  
5/1/2018Michael J AmbrogiCOOSell60,000$27.40$1,644,000.00View SEC Filing  
5/1/2018Wilhelmus Cm GroenhuysenCFOSell30,470$27.58$840,362.60View SEC Filing  
4/26/2018Michael J AmbrogiCOOSell20,000$26.01$520,200.00166,558View SEC Filing  
4/26/2018Yoram PaltiInsiderSell20,966$26.09$547,002.94View SEC Filing  
4/24/2018Yoram PaltiInsiderSell35,600$25.06$892,136.00View SEC Filing  
4/20/2018Yoram PaltiCTOSell19,362$25.06$485,211.72View SEC Filing  
4/18/2018Michael J AmbrogiCOOSell40,000$23.03$921,200.00166,558View SEC Filing  
4/18/2018Yoram PaltiInsiderSell44,072$23.65$1,042,302.80116,451View SEC Filing  
4/3/2018Yoram PaltiInsiderSell60,000$20.32$1,219,200.00View SEC Filing  
3/29/2018Yoram PaltiCTOSell30,000$21.67$650,100.00View SEC Filing  
2/23/2018Michael J AmbrogiCOOSell8,458$19.83$167,722.14105,288View SEC Filing  
2/23/2018Todd Christopher LongsworthGeneral CounselSell6,591$19.83$130,699.5326,665View SEC Filing  
2/23/2018Wilhelmus Cm GroenhuysenCFOSell13,351$19.83$264,750.33252,412View SEC Filing  
1/29/2018Asaf DanzigerCEOSell13,974$24.02$335,655.48356,790View SEC Filing  
1/29/2018Todd Christopher LongsworthGeneral CounselSell11,630$24.00$279,120.0016,628View SEC Filing  
1/24/2018Asaf DanzigerCEOSell20,848$22.10$460,740.80387,820View SEC Filing  
1/16/2018Asaf DanzigerCEOSell14,900$22.20$330,780.00398,068View SEC Filing  
1/12/2018Asaf DanzigerCEOSell336,420$22.33$7,512,258.60435,863View SEC Filing  
1/11/2018Eilon D KirsonInsiderSell25,320$22.00$557,040.003,181View SEC Filing  
1/9/2018Wilhelmus Cm GroenhuysenCFOSell31,132$21.02$654,394.64240,210View SEC Filing  
1/4/2018Wilhelmus Cm GroenhuysenCFOSell28,868$21.03$607,094.04268,568View SEC Filing  
11/13/2017Yoram PaltiInsiderSell30,000$17.13$513,900.00View SEC Filing  
11/9/2017Yoram PaltiCTOSell30,000$18.25$547,500.00View SEC Filing  
11/7/2017Yoram PaltiInsiderSell60,000$21.06$1,263,600.00View SEC Filing  
11/6/2017Asaf DanzigerCEOSell6,919$22.00$152,218.00View SEC Filing  
11/3/2017Asaf DanzigerCEOSell2,300$22.00$50,600.00756,024View SEC Filing  
11/3/2017Eilon D KirsonInsiderSell3,400$22.00$74,800.0040,701View SEC Filing  
11/3/2017Michael J AmbrogiCOOSell1,200$22.00$26,400.0024,987View SEC Filing  
11/2/2017Yoram PaltiCTOSell30,000$21.78$653,400.00View SEC Filing  
11/1/2017Asaf DanzigerCEOSell15,866$22.01$349,210.66774,040View SEC Filing  
11/1/2017Eilon D KirsonInsiderSell22,269$22.01$490,140.6963,120View SEC Filing  
11/1/2017Michael J AmbrogiCOOSell24,327$22.01$535,437.2749,514View SEC Filing  
9/25/2017Asaf DanzigerCEOSell900$22.05$19,845.00774,190View SEC Filing  
9/14/2017Asaf DanzigerCEOSell37,272$22.01$820,356.72776,862View SEC Filing  
9/13/2017Asaf DanzigerCEOSell35,500$22.01$781,355.00776,862View SEC Filing  
7/11/2017Asaf DanzigerCEOSell7,383$19.95$147,290.85462,765View SEC Filing  
7/10/2017Asaf DanzigerCEOSell274,359$18.07$4,957,667.13668,865View SEC Filing  
7/6/2017Asaf DanzigerCEOSell160,138$18.14$2,904,903.32899,462View SEC Filing  
7/5/2017Asaf DanzigerCEOSell155,088$18.14$2,813,296.32899,462View SEC Filing  
6/26/2017Pomona Capital Vii Fund InvestMajor ShareholderSell1,072,532$17.35$18,608,430.20View SEC Filing  
6/21/2017Eilon D KirsonInsiderSell66,361$16.78$1,113,537.58222,722View SEC Filing  
6/19/2017Asaf DanzigerCEOSell124,720$15.51$1,934,407.20896,917View SEC Filing  
6/19/2017Eilon D KirsonInsiderSell15,000$15.06$225,900.00289,083View SEC Filing  
6/16/2017Asaf DanzigerCEOSell42,457$15.15$643,223.551,030,849View SEC Filing  
6/14/2017Asaf DanzigerCEOSell94,102$15.22$1,432,232.441,069,496View SEC Filing  
6/12/2017Asaf DanzigerCEOSell180,601$15.13$2,732,493.131,163,296View SEC Filing  
6/12/2017Eilon D KirsonInsiderSell20,956$15.03$314,968.68319,083View SEC Filing  
6/5/2017Yoram PaltiInsiderSell3,825$13.82$52,861.50View SEC Filing  
6/2/2017Yoram PaltiInsiderSell8,000$13.27$106,160.007,825View SEC Filing  
5/31/2017Yoram PaltiInsiderSell8,000$12.49$99,920.0015,825View SEC Filing  
5/26/2017Yoram PaltiInsiderSell8,000$12.88$103,040.0023,825View SEC Filing  
5/24/2017Yoram PaltiInsiderSell4,000$13.15$52,600.0029,256View SEC Filing  
5/23/2017Yoram PaltiInsiderSell8,000$11.73$93,840.0035,825View SEC Filing  
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.0043,825View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.0047,825View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.0055,825View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.0063,825View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.0071,825View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.0079,825View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.0087,825View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.0095,825View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00103,825View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00111,825View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00119,825View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00127,825View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00143,825View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00143,825View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00143,825View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00143,825View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.006,125,000View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00139,084View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00179,084View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00179,084View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00219,084View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00259,084View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00289,084View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00299,084View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00309,084View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60676,576View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00324,084View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00933,557View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00148,114View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NovoCure (NASDAQ NVCR) News Headlines

Source:
DateHeadline
NovoCure (NVCR) Expected to Post Quarterly Sales of $58.84 MillionNovoCure (NVCR) Expected to Post Quarterly Sales of $58.84 Million
www.americanbankingnews.com - May 22 at 5:02 AM
-$0.15 EPS Expected for NovoCure (NVCR) This Quarter-$0.15 EPS Expected for NovoCure (NVCR) This Quarter
www.americanbankingnews.com - May 20 at 1:16 AM
BidaskClub Downgrades NovoCure (NVCR) to BuyBidaskClub Downgrades NovoCure (NVCR) to Buy
www.americanbankingnews.com - May 19 at 11:02 AM
Gabriel Leung Sells 80,000 Shares of NovoCure (NVCR) StockGabriel Leung Sells 80,000 Shares of NovoCure (NVCR) Stock
www.americanbankingnews.com - May 17 at 7:34 PM
3 Young Biotechs Positioned To Upend Medicine3 Young Biotechs Positioned To Upend Medicine
seekingalpha.com - May 17 at 7:09 PM
NovoCure (NVCR) Given Average Recommendation of "Buy" by AnalystsNovoCure (NVCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 17 at 10:38 AM
Insider Selling: NovoCure (NVCR) CFO Sells $281,883.93 in StockInsider Selling: NovoCure (NVCR) CFO Sells $281,883.93 in Stock
www.americanbankingnews.com - May 15 at 7:52 PM
Insider Selling: NovoCure (NVCR) CFO Sells 30,470 Shares of StockInsider Selling: NovoCure (NVCR) CFO Sells 30,470 Shares of Stock
www.americanbankingnews.com - May 15 at 7:36 PM
NovoCure (NVCR) Upgraded to "Strong-Buy" by BidaskClubNovoCure (NVCR) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - May 12 at 7:35 AM
$59.02 Million in Sales Expected for NovoCure (NVCR) This Quarter$59.02 Million in Sales Expected for NovoCure (NVCR) This Quarter
www.americanbankingnews.com - May 4 at 3:02 AM
NovoCure (NVCR) CFO Sells $840,362.60 in StockNovoCure (NVCR) CFO Sells $840,362.60 in Stock
www.americanbankingnews.com - May 3 at 7:52 PM
NovoCure (NVCR) COO Sells $1,644,000.00 in StockNovoCure (NVCR) COO Sells $1,644,000.00 in Stock
www.americanbankingnews.com - May 3 at 7:33 PM
NovoCure (NVCR) Upgraded at ValuEngineNovoCure (NVCR) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM
NovoCure (NVCR) Expected to Post Earnings of -$0.16 Per ShareNovoCure (NVCR) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 2 at 1:12 PM
Zacks Investment Research Lowers NovoCure (NVCR) to HoldZacks Investment Research Lowers NovoCure (NVCR) to Hold
www.americanbankingnews.com - May 1 at 6:36 AM
Michael J. Ambrogi Sells 20,000 Shares of NovoCure (NVCR) StockMichael J. Ambrogi Sells 20,000 Shares of NovoCure (NVCR) Stock
www.americanbankingnews.com - April 30 at 7:46 PM
Insider Selling: NovoCure (NVCR) Insider Sells 20,966 Shares of StockInsider Selling: NovoCure (NVCR) Insider Sells 20,966 Shares of Stock
www.americanbankingnews.com - April 30 at 7:28 PM
NovoCure: 2018 Off To A Strong Start For OptuneNovoCure: 2018 Off To A Strong Start For Optune
seekingalpha.com - April 30 at 5:21 PM
Novocure Hints To Additional Stellar Data And ValidationNovocure Hints To Additional Stellar Data And Validation
seekingalpha.com - April 30 at 8:10 AM
Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMTEdited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT
finance.yahoo.com - April 27 at 5:21 PM
Wedbush Boosts NovoCure (NVCR) Price Target to $33.00Wedbush Boosts NovoCure (NVCR) Price Target to $33.00
www.americanbankingnews.com - April 27 at 2:30 PM
NovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche BankNovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche Bank
www.streetinsider.com - April 27 at 8:14 AM
Investors Buy High Volume of NovoCure Put Options (NVCR)Investors Buy High Volume of NovoCure Put Options (NVCR)
www.americanbankingnews.com - April 27 at 7:44 AM
Stock Traders Purchase Large Volume of Call Options on NovoCure (NVCR)Stock Traders Purchase Large Volume of Call Options on NovoCure (NVCR)
www.americanbankingnews.com - April 27 at 7:44 AM
NovoCure (NVCR) Announces  Earnings ResultsNovoCure (NVCR) Announces Earnings Results
www.americanbankingnews.com - April 26 at 7:30 PM
Novocure (NVCR) Misses Q1 EPS by 10c, Miss on RevenuesNovocure (NVCR) Misses Q1 EPS by 10c, Miss on Revenues
www.streetinsider.com - April 26 at 5:23 PM
NovoCure: 1Q Earnings SnapshotNovoCure: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 5:23 PM
This Explains Why NovoCure Is Surging TodayThis Explains Why NovoCure Is Surging Today
finance.yahoo.com - April 26 at 5:23 PM
Novocure Reports First Quarter 2018 Financial Results and Provides Company UpdateNovocure Reports First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - April 26 at 8:07 AM
Zacks Investment Research Upgrades NovoCure (NVCR) to "Buy"Zacks Investment Research Upgrades NovoCure (NVCR) to "Buy"
www.americanbankingnews.com - April 26 at 6:10 AM
NovoCure (NVCR) Insider Yoram Palti Sells 35,600 SharesNovoCure (NVCR) Insider Yoram Palti Sells 35,600 Shares
www.americanbankingnews.com - April 25 at 7:10 PM
NovoCure (NVCR) Shares March Higher, Can It ContinueNovoCure (NVCR) Shares March Higher, Can It Continue
finance.yahoo.com - April 25 at 5:37 PM
NovoCure (NVCR) Upgraded to Buy at BidaskClubNovoCure (NVCR) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - April 24 at 9:58 AM
NovoCure (NVCR) CTO Sells $485,211.72 in StockNovoCure (NVCR) CTO Sells $485,211.72 in Stock
www.americanbankingnews.com - April 23 at 4:24 PM
NovoCure (NVCR) Given Consensus Recommendation of "Buy" by AnalystsNovoCure (NVCR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 7:48 AM
BRIEF-Novocure Says Executive Chairman William Doyles FY 2017 Total Compensation Was $23.8 MlnBRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
www.reuters.com - April 20 at 5:30 PM
NovoCure (NVCR) Insider Sells $1,042,302.80 in StockNovoCure (NVCR) Insider Sells $1,042,302.80 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM
NovoCure (NVCR) COO Sells $921,200.00 in StockNovoCure (NVCR) COO Sells $921,200.00 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM
NovoCure (NVCR) Upgraded at Deutsche BankNovoCure (NVCR) Upgraded at Deutsche Bank
www.americanbankingnews.com - April 19 at 10:01 AM
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...
globenewswire.com - April 19 at 8:07 AM
Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in MesotheliomaBlog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma
finance.yahoo.com - April 19 at 8:07 AM
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 19 at 8:07 AM
NovoCure (NVCR) Set to Announce Quarterly Earnings on ThursdayNovoCure (NVCR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:34 AM
NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in SessionNovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
finance.yahoo.com - April 18 at 5:53 PM
NovoCure (NVCR) Receives Buy Rating from MizuhoNovoCure (NVCR) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 18 at 9:00 AM
BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In MesotheliomaBRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma
www.reuters.com - April 17 at 6:06 PM
NovoCure (NVCR) Downgraded by BidaskClub to "Buy"NovoCure (NVCR) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 1:54 PM
Whats Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage MedicalWhat's Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage Medical
www.prnewswire.com - April 17 at 8:16 AM
Novocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in MesotheliomaNovocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
www.streetinsider.com - April 17 at 8:16 AM
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in MesotheliomaNovocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
finance.yahoo.com - April 17 at 8:16 AM

SEC Filings

NovoCure (NASDAQ:NVCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NovoCure (NASDAQ:NVCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NovoCure (NASDAQ NVCR) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.